The European Society of Cardiology's annual meeting is scheduled for Aug. 25-28, 2023, in Amsterdam.

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

The agency has shared a new draft guidance focused on the inclusion of information related to QTc interval prolongation. 

"You have to look at each patient and understand their goals," one HCM expert said in a new interview. 

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

Researchers shared long-term follow-up data from the Colchicine-PCI trial, which compared colchicine administration before PCI with a placebo.

Anjali Owens, MD, discussed the past, present and future of hypertrophic cardiomyopathy care in the United States. "What we are aiming to do is develop a minimum standard for assessments of patients with HCM so they are getting properly diagnosed and managed," she explained. 

Valentin Fuster, MD, PhD, one of the world’s most prominent cardiologists, said "it is now our responsibility to ensure these treatments are widely available and used by the medical community.”